A new UK-based trial will explore the potential of medical cannabis as a treatment for long-term COVID-19.
Australian medical cannabis company Bod Australia has been granted Clinical Trial Authorisation by the UK’s Medicines & Healthcare Products Regulatory Agency to study the effectiveness of medicinal cannabis on symptoms of long-term COVID-19.
The trial, which will be carried out in association with Drug Science, will examine the effectiveness of Bod’s medicinal cannabis product, MediCabilis® 5 per cent, on symptoms associated with the long-term impact of Covid-19.
Long COVID refers to persistent or new symptoms that develop at least eight weeks following an initial COVID-19 infection.
According to the Office for National Statistics (ONS), an estimated 1.3 million people in the UK currently suffer from the condition and one in every 40 people with COVID-19 experiences symptoms lasting at least three months.
Common symptoms include shortness of breath, fatigue, worsening chest discomfort, loss of concentration, chronic pain, anxiety and insomnia.
Medical cannabis products are currently widely prescribed to patients with conditions including chronic pain, anxiety and sleep disorders, so it is thought that many symptoms of long-term COVID-19 may also be amenable to this treatment.
Following the receipt of CTA, Bod has begun initiatives to commence the clinical trial, and along with Drug Science, it is now recruiting up to 30 participants over 18 suffering from long-term COVID-19.
Participants will be administered MediCabilis® daily over six months. They will undertake monthly and daily assessments of symptoms such as breathlessness, fatigue, cognition and pain via a smartphone app.
The results will determine the feasibility and safety of medicinal cannabis and MediCabilis® in the treatment of the condition.
The trial will be led by principal investigator Dr Elizabeth Iverson, who commented: “We are excited that Clinical Trial Authorisation has been granted so that we can commence this trial into the potential use of medicinal cannabis products to treat long Covid.
“Given the ongoing and global prevalence of Covid-19 and its long-term effects, it is important to take a scientifically focused approach towards the potential treatment mechanisms associated with the condition.”
Drug Science founder and chief scientific officer, Professor David Nutt, added: “Long COVID shares symptoms with disorders that medical cannabis has been proved to treat. So, this new study could be an exciting and important step for patients and our wider understanding of these medicines. Long Covid is a problem in many different countries, we hope that this UK-based research will lead to help for patients all over the world.”
Existing evidence
A recently-published study by Oregon State University revealed that cannabigerolic acid (CBGA) and cannabidiolic acid (CBDA) may prevent the virus that causes Covid-19 from entering human cells.
In a webinar hosted by the Medical Cannabis Clinicians Society last year, Dr Anjali Didi, a general practitioner based in Australia, explained how medical cannabis had helped two patients with sleep issues, anxiety and fatigue associated with long-term COVID-19.
Bod Australia CEO Jo Patterson said: “While there aren’t any existing treatments for long-COVID, our medicinal cannabis products have been used to treat and alleviate several similar conditions. We anticipate that this clinical trial will provide us with great insight into its potential to treat long-term covid and build on the body of evidence for the use of cannabis-based medicines in place of other pharmaceuticals.”
Disclaimer: https://cannabishealthnews.co.uk/2022/01/18/uk-trial-to-examine-medical-cannabis-as-treatment-for-long-covid
